Asli Bolayir, Malik Ejder Yildirim, Tugba Turker Cetinel, Seyda Figul Gokce

5474

Effects of ApaI, FokI, and BsmI gene polymorphisms of the vitamin D receptor on serum vitamin D level in Turkish MS patients with different types and severities of the disease

Effects of ApaI, FokI, and BsmI gene polymorphisms of the vitamin D receptor on serum vitamin D level in Turkish MS patients with different types and severities of the disease

Aim: Adequate vitamin D levels may reduce the risk of multiple sclerosis (MS) development and progress. It is believed that a number of genes cause the disease, including the genes that function on vitamin D metabolism, although information about the role of the said genes is quite contradictory. We aimed to investigate the status of serum vitamin D and ApaI, FokI, and BsmI gene polymorphisms of the vitamin D receptor in Turkish MS patients with different types and severities of the disease. Materials and Methods: The patients were divided into three groups in accordance with the types of MS: relapsing-remitting MS (RRMS), secondary progressive MS (SPMS), and primary progressive MS (PPMS). Serum D vitamin level was studied, and polymerase chain reaction (PCR) applications were performed by designing primers suitable for the vitamin D receptor (VDR) gene regions in which FokI (rs2228570), BsmI (rs1544410), and ApaI (rs7975232) polymorphisms are localized. The Expanded Disability Status Scale (EDSS) was utilized to determine the disability status of MS patients. Results: Although vitamin D levels were inadequate in MS patients and controls, the mean serum vitamin D level of MS patients was significantly higher than the controls (p
PDF

___

  • 1. Tsang BK, Macdonell R. Multiple sclerosis-diagnosis, management and prognosis. Aust Fam Physician 2011;40:948-55.
  • 2. Ramagopalan SV, Sadovnick AD. Epidemiology of Multiple Sclerosis. Neurol Clin 2011;29:207-17.
  • 3. Ebers GC. Environmental factors and multiple sclerosis. Lancet Neurol 2008;7:268-77.
  • 4. DeLuca GC, Kimball SM, Kolasinski J, et al. Review: The role of vitamin D in nervous system health and disease. Neuropathol Appl Neurobiol 2013;39:458-84.
  • 5. Walbert T, Jirikowski GF, Prüfer K. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat. Horm Metab Res 2001;33:525-31.
  • 6. Abdollahzadeh R, Fard MS, Rahmani F, et al. Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: A case-control study. J Neurol Sci 2016;367:148-51.
  • 7. Walbert T, Jirikowski GF, Prüfer K. Distribution of 1,25-dihydroxyvitamin D3 receptor immunoreactivity in the limbic system of the rat. Horm Metab Res 2001;33:525-31.
  • 8. Uitterlinden AG, Fang Y, van Meurs JBJ, et al. Genetics and Biology of Vitamin D Receptor Polymorphisms. Gene 2004;338:143-56.
  • 9. Chang TJ, Lei HH, Yeh JI, et al. Vitamin D receptor gene polymorphisms influence susceptibility to type 1 diabetes mellitus in the Taiwanese population. Clin Endocrinol 2000;52:575-80.
  • 10. Zhou H, Xu C, Gu M. Vitamin D receptor (VDR) gene polymorphisms and Graves' disease: a meta-analysis. Clin Endocrinol 2009;70:938-45.
  • 11. Rucević I, Barisić-Drusko V, Glavas-Obrovac L, et al. Vitamin D endocrine system and psoriasis vulgarisreview of the literature. Acta Dermatovenerol Croat 2009;17:187- 92.
  • 12. Čierny D, Michalik J, Škereňová M, et al. ApaI, BsmI and Taq I. VDR gene polymorphisms in association with multiple sclerosis in Slovaks. Neurol Res 2016;38:678-84.
  • 13. Smolders J, Peelen E, Thewissen M, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 2009;8:621- 6.
  • 14. Dendrou CA, Fugger L, Friese MA. Immunopathology of multiple sclerosis. Nat Rev Immunol 2015;15:545- 58.
  • 15. Hurwitz BJ. The diagnosis of multiple sclerosis and the clinical subtypes. Ann Indian Acad Neurol 2009;12:226-30.
  • 16. Kremenchutzky M, Cottrell D, Rice G, et al. The natural history of multiple sclerosis: a geographically based study. 7. Progressive-relapsing and relapsingprogressive multiple sclerosis: a re-evaluation. Brain 1999;122:1941-50.
  • 17. Confavreux C, Vukusic S, Moreau T, et al. Relapses and progression of disability in multiple sclerosis. N Engl J Med 2000;343:1430-8.
  • 18. Kurtzke JF. Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS). Neurology 1983;33:1444-52.
  • 19. Sambrook J, Russell DW. Purification of Nucleic Acids by Extraction With Phenol: chloroform. CSH Protoc 2006; 1: pdb.prot4455.
  • 20. Ramagopalan SV, Sadovnick AD. Epidemiology of multiple sclerosis. Neurol Clin 2011;29:207-17.
  • 21. Ghanaatian N, Lashgari NA, Abdolghaffari AH, et al. Curcumin as a therapeutic candidate for multiple sclerosis: Molecular mechanisms and targets. J Cell Physiol 2019;234:12237-48.
  • 22. Sadovnick AD, Armstrong H, Rice GP, et al. A population-based study of multiple sclerosis in twins: Update. Ann Neurol 1993;33:281-5.
  • 23. Fan Y, Zhang J. Dietary modulation of intestinal microbiota: Future opportunities in experimental autoimmune encephalomyelitis and multiple sclerosis. Front Microbiol 2019;10:740.
  • 24. Landry CS, Ruppe MD, Grubbs EG. Vitamin D Receptors and Parathyroid Glands. Endocr Pract 2011;17:63-8.
  • 25. Narvaez CJ, Zinser G, Welsh J. Functions of 1α,25- dihydroxyvitamin D3 in mammary gland: from normal development to breast cancer. Steroids 2001;66:301- 8.
  • 26. Huang CM, Wu MC, Wu JY, et al. Association of vitamin D receptor gene BsmI polymorphisms in Chinese patients with systemic lupus erythematosus. Lupus 2002;11:31-4.
  • 27. Narooie-Nejad M, Moossavi M, Torkamanzehi A et al. Positive Association of Vitamin D Receptor Gene Variations with Multiple Sclerosis in South East Iranian Population. Biomed Res Int 2015;2015:1-4.
  • 28. Orton SM, Sreeram V, Ramagopan PAE, et al. Vitamin D metabolic pathway genes and risk of multiple sclerosis in Canadians. J Neurol Sci 2011;305:116-120.
  • 29. Niino M, Fukazawa T, Yabe I, et al. Vitamin D receptor gene polymorphism in multiple sclerosis and the association with HLA class II alleles. J Neurol Sci 2000;177:65-71.
  • 30. Agliardi C, Guerini FR, Saresella M, et al. Vitamin D receptor (VDR) gene SNPs influence VDR expression and modulate protection from multiple sclerosis in HLA-DRB1*15-positive individuals. Brain Behav Immun 2011;25:1460-7.
  • 31. Tajouri L, Ovcaric M, Curtain R, et al. Variation in the vitamin D receptor gene is associated with multiple sclerosis in an Australian population. Journal of Neurogenetics 2005;19:25-38.
  • 32. Smolders J, Peelen E, Thewissen M, et al. The relevance of vitamin D receptor gene polymorphisms for vitamin D research in multiple sclerosis. Autoimmun Rev 2009;8:621-6.
  • 33. Simon KC, Munger KL, Xing Y, et al. Polymorphisms in vitamin D metabolism related genes and risk of multiple sclerosis. Mult Scler J 2010;16:133-8.
  • 34. Bettencourt A, Bolexixa D, Guimaaes AL, et al. The vitamin D receptor gene FokI polymorphism and Multiple Sclerosis in a Northern Portuguese population J Neuroimmunol 2017;309:34-7.
  • 35. Bermúdez-Morales VH, Fierros G, Lopez RL, et al. Vitamin D receptor gene polymorphisms are associated with multiple sclerosis in Mexican adults. J Neuroimmunol 2017;306:20–4.
  • 36. Agnello L, Scazzone C, Ragonese P, et al. Vitamin D receptor polymorphisms and 25- hydroxyvitamin D in a group of Sicilian multiple sclerosis patients. Neurol Sci 2016;37:261-7.
Annals of Medical Research-Cover
  • Yayın Aralığı: 12
  • Yayıncı: İnönü Üniversitesi Tıp Fakültesi
Arşiv
Sayıdaki Diğer Makaleler

Prognostic factors and classification of pathological single and multiple N1 in non-small cell lung cancer patients

Ali Cevat Kutluk, Muzaffer Metin, Cemal Aker, Volkan Erdogu, Atilla Pekcolaklar, Ozkan Saydam, Deniz Sansar, Selin Onay

Efficacy and safety of ruxolitinib plus extracorporeal photopheresis in acute and chronic graft versus host disease: A single center experience

Emin Kaya, Omer Faruk Bahcecioglu, Selim Gok, Mehmet Ali Erkurt, Irfan Kuku, Ahmet Sarici, Ilhami Berber, Soykan Bicim, Lokman Hekim Tanriverdi, Mustafa Ozgul

Can melatonin correct the negative effect of experimental diabetes created during the maternal period on fetal rat development and puppies cognitive functions?

Bahri Evren, Emek Guldogan, Sema Tulay Koz, Yusuf Ozkan

Angiographic embolization in epistaxis: Our clinical experience and results

Ismail Okan Yildirim, Kaya Sarac, Mehmet Tan, Tuba Bayindir, Mehmet Turan Cicek, Mehmet Aslan, Ebru Ozer Ozturk

Melkersson-Rosenthal syndrome: Still arousing clinician interest!

Ilyas El Kassimi, Adil Rkiouak, Youssef Sekkach

A rare anterior mediastinal mass: Giant Thymolipoma

Hilal Er Ulubaba, Rukiye Ciftci

Investigation of hepatitis B virus prevalence and reactivation frequency in malignancy patients administering chemotherapy

Yasir Furkan Cagin, Muhammet Cengiz, Yuksel Seckin, Ayse Nuransoy Cengiz

The value of posttreatment CA125 and PET/CT in predicting prognosis of epithelial ovarian cancer

Emine Budak, Mehmet Ozeren, Gokhan Tosun, Abdurrahman Hamdi Inan, Ahkam Goksel Kanmaz, Emrah Beyan, Adnan Budak, Alper Ileri, Onur Suleyman Aldemir

Nm23 and HER2/neu gene expression and prognostic significance in urothelial carcinomas of the bladder

Remzi Arslan, Fazli Erdogan

Factors effecting the development of sentinel lymph node metastasis in clinical early-stage breast cancers (cT1-2N0): Clinical significance of primary tumor – skin distance

Azmi Lale, Erhan Aygen, Hatice Nur Lale, Levent Zirek, Merve Zirek, Ali Cihan Yildirir